ALK-Abelló

Regulatory Filings • Feb 9, 2015

Copenhagen, 2015-02-09 09:00 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) and bioCSL announce a partnership in
Australia and New Zealand which grants bioCSL exclusive rights to promote and
sell ALK’s SLIT-tablets against house dust mite and grass pollen allergy, and
ALK’s Jext® adrenaline auto-injector.

ALK and bioCSL today announced that they have entered into a long-term
partnership covering three ALK products in Australia and New Zealand. The
agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s
sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite
(HDM) allergy and grass pollen allergy (marketed as GRAZAX® in Europe and
GRASTEK® in North America), and its adrenaline auto-injector, Jext®. ALK will
be responsible for product supply and bioCSL will undertake registration and
commercialisation of the products.

Allergic rhinitis is one of the most common respiratory illnesses in Australia
and affects approximately 18% of the population.1 Furthermore, it frequently
coexists with other allergic conditions such as asthma and sinusitis.1 The
disease may impact many aspects of life such as sleep, social and leisure
activities, work and general day to day functioning.2

“We recognise that access to more therapy options is very important to
Australian healthcare professionals and allergy sufferers,” said bioCSL’s
General Manager, Dr John Anderson. “We are delighted to work with ALK for the
distribution, marketing and sales of these products which are important
additions to bioCSL’s growing product range and further strengthens our broad
portfolio of in-licensed medicines in Australia,” he said.

As part of the agreement, ALK will receive a minor upfront payment of an
undisclosed amount, followed by a milestone payment upon approval of the HDM
SLIT-tablet in Australia. ALK will sell products to bioCSL at a pre-agreed
price structure ensuring a certain split of the final in-market revenues
generated by bioCSL.

Jens Bager, President and CEO of ALK says: “Expanding the reach of ALK’s
products by entering new growth markets is an important part of our strategy.
bioCSL is an attractive partner being a large local pharmaceutical company in
Australia with a prominent track record in vaccines and adrenaline
auto-injectors. Australia and New Zealand are markets with resilient economies,
substantial allergy prevalence and developing allergy immunotherapy markets.”

The partnership with bioCSL advances ALK’s strategy of broadening its
geographical presence through partnerships, acquisitions or by establishing its
own affiliates.

This announcement does not impact ALK’s financial guidance for 2015.

                             ALK-Abelló A/S

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

References:
1 ASCIA 2014. Allergy in Australia 2014. A submission for allergic diseases to
be recognised as a National Health Priority Area
2 AIHW 2011, Allergic rhinitis (‘hay fever’) in Australia. Cat no. ACM 23.
Canberra: AIHW

About bioCSL
In Australia and New Zealand, bioCSL markets a comprehensive range of vaccines
and pharmaceutical products. It manufactures seasonal and pandemic influenza
vaccine for global markets. bioCSL also produces products of national
significance for Australia, including antivenoms and Q-Fever vaccine, and
supplies diagnostic reagents in the Australasia region. bioCSL’s cold-chain
logistics business provides services for bioCSL and CSL Behring products, as
well as commercial and government customers across Australia.

bioCSL is part of the CSL Group which is headquartered in Melbourne Australia.
The CSL Group includes CSL Behring, CSL Plasma and bioCSL, and has major
facilities in Australia, Germany, Switzerland and the USA, with over 13,000
employees working in more than 27 countries. Find more information at
www.biocsl.com.au.

About allergy in Australia
Allergies are the fastest growing chronic diseases in Australia and include
allergic rhinitis (hay fever), allergic asthma, food, insect and drug
allergies, and eczema. Approximately 20% of the Australian population have at
least one allergic disease. Allergic disease most commonly presents in children
and adolescents and often persists into adulthood with significant impact on
quality of life. It is predicted that by 2050 there will be 7.7 million
Australians affected by allergic diseases, an increase of 70% from current
estimates2.

The Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy
& Anaphylaxis Australia (A&AA), the leading medical and patient organisations
for allergy in Australia, are developing a National Allergy Strategy for
Australia, whereby allergic diseases would be recognised as a National Health
Priority Area and a prioritised as a chronic disease2.

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy – a unique treatment of the underlying cause of allergy. The
company has approximately 1,800 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii to commercialise sublingual allergy
immunotherapy tablets in North America and Japan, respectively. The company is
headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more
information at www.alk.net.